

HMP Global's 2024 Advances in Inflammatory Bowel Diseases (AIBD) program focuses on highest standard in IBD care

Annual conference recognizes prestigious Sherman Prize recipients; introduces preconference workshop for APPs; features new pharmacy learning track.

MALVERN, PA, UNITED STATES,
November 21, 2024 /

EINPresswire.com/ -- HMP Global's Advances in Inflammatory Diseases (AIBD) this year features a powerful educational program enhanced by a pre-conference workshop for advanced practice practitioners (APPs) and a new pharmacy learning track, delivering an overall learning experience empowering clinicians to provide the highest standard in IBD care.



AIBD will feature more than 100 sessions led by 75 expert faculty presenters, and more than 150 abstracts sharing the latest research in IBD.

AIBD 2024, the only conference of its kind focused on IBD, will be held December 9-11 at Walt Disney World Dolphin Hotel in Orlando, Florida. The program covers three days of real-world clinical education, comprehensive case studies, new evidence-based approaches in IBD management, and access to leading experts who are essential to providing optimal treatment strategies for patients with IBD.

"Advances in IBD is a transformative journey that seamlessly blends scientific innovation with practical solutions, steering the course for the future of IBD management," said Co-Chair Stephen Hanauer, MD, MACG, Medical Director of Digestive Health Center, Northwestern University Feinberg School of Medicine. "AIBD is an unparalleled experience in which we redefine standards, introduce groundbreaking therapies, and showcase the latest in technological advancements and real-world data."

Kicking off the conference are five preconference workshops on December 8, including a new workshop for APPs where participants will split into groups to discuss a revolving set of topics in IBD, including preceptorships, publications, and new and under-utilized therapies.



AIBD is an unparalleled experience in which we redefine standards, introduce groundbreaking therapies, and showcase the latest in technological advancements and real-world data.”

*Co-Chair Stephen Hanauer,
MD, MACG*

Returning this year are the popular preconference workshops on Building an IBD Center; the PANCCO Symposia with educational content delivered fully in Spanish; a Fellows Workshop followed by a reception with fellows and AIBD Ambassadors; and the Women in IBD Leadership Workshop where attendees and faculty experts will participate in breakout discussions on topics relevant to women in the IBD field.

The 2024 program will include four learning tracks: Surgery, Pediatrics, Nursing and, new this year, a Pharmacy track focusing on the integration of pharmacists into IBD care, navigating the landscape of dual therapies and

resources available for medications.

2024 Sherman Prize Recipients

Each year at AIBD, pioneering IBD professionals from a variety of disciplines who exemplify excellence in areas of Crohn’s disease and ulcerative colitis are honored with the prestigious Sherman Prize. This year’s honorees will be recognized on December 10, and include:

- Millie D. Long, MD, MPH, Professor of Medicine; Interim Division Chief; Fellowship Program Director, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine at Chapel Hill;
- Dermot P.B. McGovern, MBBS, D. Phil (Oxon), FRCP (Lon), FACP, AGAF, Director of Translational Medicine at the F. Widjaja Inflammatory Bowel Disease Institute; Director of the Precision Medicine Initiative; Professor of Medicine and Biomedical Sciences; Joshua L. and Lisa Z. Greer Endowed Chair in IBD Genetics; Cedar-Sinai Medical Center; and
- Jordan E. Axelrad, MD, MPH, Associate Professor, Division of Gastroenterology and Hepatology, Department of Medicine, NYU Grossman School of Medicine; Co-Director, Inflammatory Bowel Disease Center at NYU Langone Health.

Each of these Sherman Prize recipients has made exceptional and significant contributions to the fight to overcome IBD and have met challenges with novel approaches that serve as a lasting inspiration to others.

AIBD will feature more than 100 sessions led by 75 expert faculty presenters, and more than 150 abstracts sharing the latest research in IBD. It will welcome more than 2,000 participants from around the globe, including gastroenterologists, nurses, physicians, surgeons, and other healthcare professionals interested in improving care and outcomes for patients with IBD.

For more information, visit: hmpglobalevents.com/aibd.

ABOUT HMP GLOBAL

HMP Global is the omnichannel market leader in healthcare events, education, and insight — with a mission to improve patient care. For 40 years, the company has built trusted brands including Psych Congress, the premier source for mental health education, and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. HMP Global partners with leading experts around the world to deliver more than 450 annual events, medical strategy, and marketing for pharmaceutical and medical device customers through HMP Collective, and pharmaceutical market insight, engaging a global community of healthcare stakeholders that includes nearly 2 million clinicians across 600 medical specialties as well as managed care, behavioral health, senior living, emergency medical, and pharmaceutical commercialization professionals. For more information, follow HMP Global on [LinkedIn](#) or visit hmpglobal.com.

Sandi Beason, APR

HMP Global

pr@hmpglobal.com

Visit us on social media:

[Facebook](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/761618359>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.